{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:40:34Z","timestamp":1792626034685,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032317","name":"NewAmsterdam Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ajpc.2026.101547","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:18:39Z","timestamp":1774358319000},"page":"101547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Obicetrapib safety analysis: Pooled phase 3 clinical trial experience"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-2548","authenticated-orcid":false,"given":"Adam J","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John JP","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ditmarsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collette","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Kling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L.","family":"Wicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpc.2026.101547_bib0001","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s11883-022-01070-2","article-title":"CETP inhibitors: should we continue to pursue this pathway?","volume":"24","author":"Nicholls","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ajpc.2026.101547_bib0002","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bcp.12380","article-title":"Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a Selective Cholesteryl Ester Transfer Protein (CETP) inhibitor, in healthy subjects","volume":"78","author":"Ford","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajpc.2026.101547_bib0003","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101547_bib0004","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101547_bib0005","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101547_bib0006","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Group","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101547_bib0007","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MOL.0000000000000854","article-title":"Can we revive CETP-inhibitors for the prevention of cardiovascular disease?","volume":"33","author":"Nicholls","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ajpc.2026.101547_bib0008","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70010","article-title":"Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: an integrated summary of results from non-human primate studies and clinical trials","volume":"12","author":"Nicholls","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.ajpc.2026.101547_bib0009","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ahj.2024.05.002","article-title":"Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN","volume":"274","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.ajpc.2026.101547_bib0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101547_bib0011","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ajpc.2026.101547_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.101303","article-title":"Efficacy and safety of obicetrapib in patients with dyslipidemia: an updated meta-analysis of randomized controlled trials","volume":"24","author":"Araujo","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.ajpc.2026.101547_bib0013","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/ehjcvp\/pvac025","article-title":"The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis","volume":"8","author":"Dangas","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ajpc.2026.101547_bib0014","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCGENETICS.108.817304","article-title":"Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 Initially Healthy Women from the Women's Genome Health Study","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.ajpc.2026.101547_bib0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11883-020-00853-9","article-title":"Statins in a distorted mirror of media","volume":"22","author":"Nelson","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ajpc.2026.101547_bib0016","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40265-024-01995-9","article-title":"Long-term efficacy and tolerability of PCSK9 targeted therapy: a review of the literature","volume":"84","author":"Schonck","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ajpc.2026.101547_bib0017","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101547_bib0018","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/jamacardio.2022.1276","article-title":"Macular degeneration and CETP inhibition","volume":"7","author":"Tall","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ajpc.2026.101547_bib0019","first-page":"685","article-title":"Patterns of statin use in a real-world population of patients at high cardiovascular risk","volume":"22","author":"Lin","year":"2016","journal-title":"J Manag Care Spec Pharm"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726001418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726001418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:10:40Z","timestamp":1792624240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667726001418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":19,"alternative-id":["S2666667726001418"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101547","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obicetrapib safety analysis: Pooled phase 3 clinical trial experience","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101547","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101547"}}